Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.404 5-jähriger Impact-Faktor: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2013006813
pages 137-164

The Immune System in the Pathogenesis of Ovarian Cancer

Bridget Charbonneau
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905
Ellen L. Goode
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905
Kimberly R. Kalli
Division of Oncology, Mayo Clinic, Rochester, MN 55905
Keith L. Knutson
Department of Immunology, Mayo Clinic, Rochester, MN 55905
Melissa S. DeRycke
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905

ABSTRAKT

Clinical outcomes in ovarian cancer are heterogeneous even when considering common features such as stage, response to therapy, and grade. This disparity in outcomes warrants further exploration into tumor and host characteristics. One compelling host characteristic is the immune response to ovarian cancer. While several studies have confirmed a prominent role for the immune system in modifying the clinical course of the disease, recent genetic and protein analyses also suggest a role in disease incidence. Recent studies also show that anti-tumor immunity is often negated by immune suppressive cells present in the tumor microenvironment. These suppressive immune cells also directly enhance the pathogenesis through the release of various cytokines and chemokines, which together form an integrated pathologic network. Thus, future research into immunotherapy targeting ovarian cancer will likely become increasingly focused on combination approaches that simultaneously augment immunity while preventing local immune suppression or by disrupting critical cytokine networks.


Articles with similar content:

Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada
Regulation of Chemokine Expression in the Tumor Microenvironment
Critical Reviews™ in Immunology, Vol.34, 2014, issue 2
Anton V. Gorbachev, Robert L. Fairchild
From Targets to Targeted Therapies in Hepatocellular Carcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Melchiorre Cervello, Antonella Cusimano, Maria Rita Emma, Antonina Azzolina, Giuseppa Augello, James A. McCubrey, Daniele Balasus
Glycosylated Cationic Liposomes for Cell-Selective Gene Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 2
Junzo Nakamura, Mitsuru Hashida, Koyo Nishida, Fumiyoshi Yamashita
Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Ruifang Sun, Ken H. Young, Jinfen Wang